Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Rhea-AI Summary

Karyopharm (Nasdaq: KPTI) will join a Cantor-hosted virtual fireside chat on June 8, 2026 at 12:00 p.m. ET. The webcast will feature senior management and Robert Coleman, MD, Principal Investigator of the Phase 3 XPORT-EC-042 endometrial cancer trial, with a replay available the same day.

News Market Reaction – KPTI

+0.78%

10 alerts

+0.78% Session close to close

-3.0% Trough in 1 hr 30 min

$198.53M Market Cap

0.2x Rel. Volume

In the Jun 4 session, KPTI gained 0.78%, reflecting a mild positive market reaction. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights an upcoming June 8, 2026 webcast focused on endometrial cancer, featuri...

Analysis

This announcement highlights an upcoming June 8, 2026 webcast focused on endometrial cancer, featuring senior management and the Phase 3 XPORT-EC-042 Principal Investigator. It follows a series of major Phase 3 readouts and investor events in myelofibrosis. Investors may track how this KOL discussion complements prior data, while also monitoring the impact of the recently effective resale registration for 8,843,036 shares and larger equity incentive and purchase plans.

Key Figures

Registered resale shares: 8,843,036 shares Outstanding shares in resale: 1,030,354 shares Pre-funded warrant shares: 3,391,164 shares +5 more

8 metrics

Registered resale shares 8,843,036 shares S-3 resale registration statement

Outstanding shares in resale 1,030,354 shares Portion of S-3 registered shares

Pre-funded warrant shares 3,391,164 shares Shares issuable upon exercise of pre-funded warrants

Warrant shares 4,421,518 shares Shares issuable upon exercise of warrants

Private placement proceeds $30 million Gross proceeds from March 2026 private placement

Ownership cap 9.99% Beneficial ownership limit on warrant exercises

Equity plan increase 3,000,000 shares Additional shares under 2022 Equity Incentive Plan (8-K)

ESPP increase 1,400,000 shares Added to Amended & Restated 2013 Employee Stock Purchase Plan

Historical Context

5 past events · Latest: Jun 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 02	SENTRY data highlight	Positive	-6.0%	Late-breaking SENTRY Phase 3 data selected for EHA 2026 oral session.
Jun 02	SENTRY trial results	Positive	-6.0%	ASCO 2026 late-breaking SENTRY results with improved SVR35 and OS signal.
Jun 01	Inducement equity grant	Neutral	-6.0%	Inducement RSU award to a new employee under stock incentive plan.
Jun 01	Investor call on SENTRY	Positive	+7.9%	Investor conference call to discuss SENTRY Phase 3 data after ASCO.
May 28	Conference participation	Neutral	+1.4%	Announcement of participation in 2026 Jefferies Global Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: strong positive SENTRY Phase 3 data drew a negative move, while an earlier SENTRY-focused call produced a solid gain, indicating inconsistent trading responses to news.

Recent Company History

Over the past week, Karyopharm released multiple updates around its Phase 3 SENTRY trial in myelofibrosis, including late-breaking presentations at ASCO 2026 and EHA 2026, with notable efficacy and survival data but a co-primary symptom endpoint miss. An investor call on June 2, 2026 generated a positive price reaction, while subsequent SENTRY headlines coincided with declines. Prior conference-participation news on May 28 saw a modest gain. Today’s endometrial cancer KOL webcast fits the pattern of ongoing investor engagement events.

Key Terms

phase 3

1 terms

phase 3 medical

"Principal Investigator of the Phase 3 XPORT-EC-042 trial."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will participate in a virtual fireside chat hosted by Cantor on June 8, 2026 at 12:00 p.m. ET. The event will feature the Company's senior management team and Robert Coleman, MD, FACOG, FACS, a globally recognized gynecologist oncologist and Principal Investigator of the Phase 3 XPORT-EC-042 trial.

Institutional investors interested in attending the live event should contact their Cantor representative. A replay of this event will be available on June 8, 2026 at approximately 2:00pm ET under "Events and Presentations" in the Investors & Media section of the Company's website.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm. 

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-in-webcast-featuring-endometrial-cancer-key-opinion-leader-on-june-8-2026-302790528.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is the Karyopharm (KPTI) endometrial cancer webcast with Cantor scheduled?

The Karyopharm webcast with Cantor is scheduled for June 8, 2026 at 12:00 p.m. ET. According to Karyopharm, this virtual fireside chat will feature its senior management team and focus on its endometrial cancer program.

Who is the key opinion leader speaking at Karyopharm’s June 8, 2026 KPTI webcast?

The webcast will feature Robert Coleman, MD, FACOG, FACS, a gynecologic oncologist. According to Karyopharm, he is the Principal Investigator of the Phase 3 XPORT-EC-042 endometrial cancer trial and will join the company’s senior management team.

How can institutional investors attend the Karyopharm (KPTI) endometrial cancer webcast on June 8, 2026?

Institutional investors can attend by contacting their Cantor representative. According to Karyopharm, the event is a virtual fireside chat hosted by Cantor and is designed for institutional investors interested in the company’s oncology programs.

Will a replay be available for the Karyopharm (KPTI) June 8, 2026 webcast?

Yes, a replay will be available on June 8, 2026 at about 2:00 p.m. ET. According to Karyopharm, investors can access it under “Events and Presentations” in the Investors & Media section of the company’s website.

What is the focus of the Phase 3 XPORT-EC-042 trial discussed by Karyopharm (KPTI)?

The webcast will highlight the Phase 3 XPORT-EC-042 endometrial cancer trial. According to Karyopharm, Principal Investigator Robert Coleman, MD, will participate in the discussion alongside the company’s senior management during the Cantor-hosted virtual fireside chat.

What type of event is Karyopharm (KPTI) holding with Cantor on June 8, 2026?

Karyopharm is participating in a virtual fireside chat hosted by Cantor. According to Karyopharm, the event will feature senior management and a key opinion leader in gynecologic oncology, focusing on the company’s endometrial cancer Phase 3 program.